Active immunization against hepatitis B virus (HBV) with low-doses of plasma-derived vaccine by intradermal route: anti-HBs response after therr years of follow-up

Carrilho, Flair José; Queiróz, Maria Lúcia; Fonseca, Luís; Obara, Leda H.; Silva, Luiz Caetano da

doi:10.1590/s0036-46651991000200013

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low dose immunisation schedules, using either plasma derived or yeast derived vaccines given intradermally, have been tried successfully in Brazilian health care workers78 79 and in Venezuelan medical students.80 Seroconversion rates and levels of anti-HBs achieved after low intradermal doses were comparable to those obtained with standard intramuscular doses. Moreover, 91.4% of vaccinated health workers showed anti-HBs levels over 11 times the cut off level (that is, the level considered a good antibody response) 36 months later.…”

Section: Diagnosis and Prevention Of Hbv Infection In South Americamentioning

confidence: 95%

“…Moreover, 91.4% of vaccinated health workers showed anti-HBs levels over 11 times the cut off level (that is, the level considered a good antibody response) 36 months later. 79 Local vaccine production or access to cheaper sources of HBV vaccines have been proposed as alternative solutions.20 In this respect, a genetically engineered Cuban HBV vaccine is currently being commercialised successfully in several South American countries.8' Ensuring that the market price of HBV vaccines is proportional to the particular economic capabilities of each country in the region is essential if mass control programmes are to be carried out effectively.…”

Section: Diagnosis and Prevention Of Hbv Infection In South Americamentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis B and hepatitis delta virus infection in South America.

Torres

1996

Gut

View full text Add to dashboard Cite

About 100 000 cases of acute hepatitis B virus (HBV) infection occur annually in South America. The overall prevalence of HBV infection in low risk populations ranges from 6.7% to 41%, while hepatitis B surface antigen (HBsAg) rates range from 0.4% to 13%. In high endemicity aboriginal or rural populations, perinatal transmission may play a major part in the spread of HBV. In urban populations, however, horizontal transmission, probably by sexual contact, is the predominant mode of spread, with higher rates of HBV positivity in lower socioeconomic groups. High risk populations such as health care workers and haemodialysis patients show higher rates of HBV infection than comparable populations elsewhere. The risk of posttransfusion hepatitis B remains high in some areas. Concomitant HBV infection may accelerate the chronic liver disease seen in decompensated hepatosplenic schistosomiasis. In the north, the prevalence of hepatitis delta virus (HDV) infection ranks among the highest in the world. In the south, the problem appears negligible although it is increasing within high risk urban communities. HDV superinfection has been the cause of large outbreaks offulminant hepatitis. The cost ofcomprehensive or mass vaccination programmes remains unaffordable for most South American countries. Less expensive alternatives such as low dose intradermal schedules of immunisation have been used with success in selected adult subjects. (Gut 1996; 38 (suppl 2): S48-S55)

show abstract

Section: Diagnosis and Prevention Of Hbv Infection In South Americamentioning

confidence: 95%

Section: Diagnosis and Prevention Of Hbv Infection In South Americamentioning

confidence: 99%